Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder ...

Taking a new tack There's no word yet on the drug targets that will be explored in the Cerevance partnership, but Merck head of neuroscience discovery, Jason Uslaner, said that the collaboration ...

Earlier in October, Jason Trennert, Strategas Research Partners ... beating its benchmark by 150 percentage points (see more ...

"We're excited to achieve the first milestone of our collaboration with Merck and continue our work to improve biologic manufacturing production," said Jason Kelly, CEO and co-founder, Ginkgo Bioworks ...

“The use of the PET ligand for better understanding the disease process itself will be very valuable,” says Jason Uslaner, VP, Research Science at Merck. “What levels of alpha-synuclein and ...

Ginkgo provides update on its restructuring process including an acceleration of site consolidation initiatives and continued progress on cost reductions Ginkgo signs ...

In a report released yesterday, Jason Zemansky from Bank of America Securities maintained a Hold rating on Arcus Biosciences (RCUS – ...

Omitting Merck has been a boon in 2023 ... analyst Tiffany Li joined Rothschild in 2016 with 10 years of experience. Jason Smith started as an investor in 2002 and has covered materials, energy ...

Updated clinical data from VISTA101 presented at SITC 2024.Monotherapy arm fully enrolled and combination arm expected to be fully enrolled by ...

In this article, we are going to take a look at where Merck & Co. Inc. (NYSE ... Earlier in October, Jason Trennert, Strategas Research Partners chairman and CEO, joined CNBC to discuss the ...

Omitting Merck has been a boon in 2023 ... analyst Tiffany Li joined Rothschild in 2016 with 10 years of experience. Jason Smith started as an investor in 2002 and has covered materials, energy ...